To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Glaucoma Symposium Report These symposia proceedings, and the Symposium itself, have been produced and paid for by Santen Back to the Future – Has Medical Treatment of Glaucoma Improved? Proceedings of a Symposium Presented at the European Society of Ophthalmology 2015 Congress in Vienna, Austria on 8 June 2015 Chairman and Expert Reviewer: Carlo E Traverso Symposium Speakers: Norbert Pfeiffer, 1 Gábor Holló 2 and Lutz E Pillunat 3 1. Department of Ophthalmology, Mainz University, Germany; 2. Glaucoma Service and Perimetry Unit, Department of Ophthalmology, Semmelweis University, Budapest, Hungary; 3. University – Eye Hospital Dresden, Germany Abstract These proceedings are based on a symposium that were presented at the European Society of Ophthalmology 2015 Congress in Vienna, Austria on 8 June 2015. The symposium was arranged to bring together leaders in ophthalmology to explore advances in the medical treatment of glaucoma. Many patients with glaucoma require combination therapy. Fixed-dose combinations represent a significant improvement in the medical treatment of glaucoma, being advantageous in terms of their association with good compliance and elimination of the wash-out effect. While preservatives are a historic necessity, their use is associated with increased ocular surface disease and higher indirect cost. The novel preservative-free tafluprost/timolol fixed-dose combination provides mean diurnal intraocular pressure (IOP) lowering of up to 40 % from baseline and demonstrates similar efficacy with other prostaglandin/timolol fixed-dose combinations, is superior to its individual components and non-inferior to its individual components given concomitantly. The tafluprost/timolol fixed-dose combination is well-tolerated with low prevalence of hyperaemia. It is generally accepted that function loss follows structural damage and that normal-pressure glaucoma (NPG) and high-pressure glaucoma (HPG) represent that same disease, separated by an arbitrary pressure level. However, functional damage (pattern electroretinogram) is detectable prior to structural damage and NPG patients show less retinal nerve fibre layer and visual field loss compared with the same optic nerve head morphology HPG patients. NPG patients seem to lose connective tissue first whereas, in HPG, patients seem to lose retinal nerve fibres first. Thus, whether NPG and HPG are the same disease is an open question. Keywords Fixed-dose combinations, glaucoma, preservative free, tafluprost/timolol, high-pressure glaucoma (HPG), normal-pressure glaucoma (NPG) Disclosure: Carlo E Traverso has received grants from Alcon, Allergan, Santen and Théa. Norbert Pfeiffer has received research grants from Santen, Alcon, Novartis and Allergan and speakers’ honoraria from Santen, Alcon and Allergan. Gábor Holló is a Consultant for Alcon and Santen. Lutz E Pillunat has received lecture fees from Allergan and Santen and is on the Advisory Board for Allergan and Santen, and received grant support from Novartis. Acknowledgements: Editorial assistance was provided by Catherine Amey at Touch Medical Media and funded by Santen. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. Received: 10 September 2015 Published Online: 21 December 2015 Citation: European Ophthalmic Review, 2015;9(2):132–7 Correspondence: Carlo E Traverso, Clinica Oculistica, V. le Benedetto XV, 5 – 16132, Genova, Italy. E: Support: These symposia proceedings and the symposium itself have been produced and paid for by Santen. The views and opinions expressed are those of the authors and not necessarily those of Santen. This article reports the proceedings of a sponsored satellite symposium held at the European Society of Ophthalmology 2015 Congress and as such has not been subject to the journals usual peer-review process. The report was reviewed for scientific accuracy by the symposium chairman before publication. New medical formulations for the treatment of glaucoma are likely to improve outcomes for patients. A novel preservative-free tafluprost/timolol fixed-dose combination has been shown, in clinical trials, to effectively lower intraocular pressure (IOP) and appears to be well tolerated. A satellite symposium was held at the European Society of Ophthalmology (SOE) congress in Vienna, Austria on the 8 June 2015 to look to the future and ask: has medical treatment of glaucoma improved? Prescribing Information for tafluprost/timolol can be found on page 137 132 TOU C H ME D ICA L ME D IA